Background: One-third of infants with persistent pulmonary hypertension of the newborn (PPHN) do not respond to inhaled nitric oxide (iNO). If iNO is not delivered to the pulmonary vasculature because of parenchymal lung disease, it cannot interact with hemoglobin to form methemoglobin (MHb).
Introduction
Persistent pulmonary hypertension of the newborn (PPHN) is a syndrome of failed circulatory adaptation at birth resulting in neonatal respiratory failure. 1 PPHN is often secondary to parenchymal lung disease, such as respiratory distress syndrome, meconium aspiration, blood aspiration or pneumonia. PPHN with or without associated parenchymal lung disease has been estimated to occur in 2 to 6 per 1000 live births and is associated with high morbidity and mortality. 1, 2 Inhaled nitric oxide (iNO) is the only approved selective pulmonary vasodilator for the treatment of PPHN in neonates. 3, 4 Oxygenation response to iNO has been classified as absent (<10 mm Hg increase in PaO 2 ) or present (X10 mm Hg) in the absence of any changes in inspired oxygen or ventilator settings. 5 Approximately one-third of neonates with PPHN fail to respond to iNO. [5] [6] [7] [8] The reasons for a lack of response to iNO are not clear. Potential mechanisms include (1) vascular remodeling or maldevelopment, (2) abnormalities of other vasoactive pathways, (3) inactivation of NO by superoxide anions, 9 (4) dysfunctional signaling downstream of NO (downregulation of soluble guanylyl cyclase or induction of phosphodiesterase 5 enzymes 10 in pulmonary vascular smooth muscle cells) or (5) failure of drug delivery to resistance-level pulmonary vessels. 1 It has been suggested that poor lung inflation with inadequate alveolar recruitment is the most common cause of poor NO delivery and treatment failure. 11 However, there are no studies evaluating the delivery of NO to the pulmonary vasculature and oxygenation response in PPHN.
A test to assess the delivery of iNO to pulmonary vasculature is not currently available. If poor NO delivery is suspected to be the cause of lack of improvement in oxygenation, measures such as lung recruitment (increased mean airway pressure and surfactant) or dose escalation may improve oxygenation.
If iNO reaches the alveolus and pulmonary capillaries, it interacts with hemoglobin in the RBCs to form methemoglobin (MHb). In infants with parenchymal lung disease and suboptimal inflation, inhaled NO does not reach the alveolus and cannot reach the pulmonary vessels and RBCs. As MHb levels are routinely measured after initiation of iNO therapy, these levels may provide an indication of optimal delivery of NO to pulmonary vasculature.
After exposure to inhaled iNO, the increase in MHb levels are dependent on the dose of NO 12, 13 and the duration of exposure. 
Results
Seventy-four infants with PPHN received iNO during this period. Twenty-two infants were excluded: seven with congenital diaphragmatic hernia, two with black-lung PPHN, five with pulmonary hypoplasia, six who did not have MHb levels drawn during the first 12 h of iNO therapy and two who did not have an arterial blood gas before initiation of NO. Fifty-two infants were analyzed. Arterial blood gas after iNO was obtained 48 ± 7 min after initiation of iNO. This blood gas sample was compared with the arterial blood gas sample immediately preceding inhaled NO. Sixteen infants did not respond to iNO with a change in PaO 2 /F iO2 ratio ranging from -30 to þ 5 mmHg (median -9, IQR -17, -1). Thirty-six infants responded to iNO with a change in PaO 2 /F iO2 ratio ranging from þ 10 to þ 156 mm Hg (median 86, IQR 43, 112). These two groups of infants had similar gestational age and birth weight ( Table 1 ). All infants received iNO within 24 h of birth with one exception in each group, in which it was initiated on the second day of life. Use of inotropic medications (dopamine) was more common among non-responders as compared with responders. Response to iNO and the incidence of extracorporeal membrane oxygenation (ECMO) or death were different between responders and non-responders ( Table 2 ). The majority of the infants were started on 20 ppm (occasionally 5 or 10 ppm) of iNO. Oxygen requirement decreased significantly and arterial oxygenation improved among responders. Four infants among non-responders required ECMO. Of these four patients, one infant with pneumonia and sepsis died on ECMO. Among responders, one infant with blood aspiration had an initial response to iNO, but deteriorated later requiring ECMO.
The initial MHb levels (expressed as a percent of total hemoglobin) were similar among non-responders and responders (Table 3 ). The range of initial MHb was 0.5 to 1.4% among non-responders and 0.4 to 2% among responders. The dose of Methemoglobin and response to NO MJ Pabalan et al iNO and duration of exposure at the time of assessment of initial MHb level were similar between the two groups. The initial MHb/SNO ratio was significantly lower among non-responders compared with responders (0.024 ± 0.012 vs 0.07 ± 0.053).
There was a significant correlation between change in PaO 2 /FiO 2 and MHb/SNO ratios by simple regression (Figure 1 ).
Discussion
Enhancing the oxygenation response to iNO in infants with PPHN will decrease the need for an invasive ECMO procedure. In this study, we showed for the first time that MHb level corrected for iNO exposure, an indirect marker of iNO delivery, correlates with the degree of improvement in oxygenation in PPHN secondary to parenchymal lung disease. The baseline characteristics of infants with PPHN who did not respond to iNO were similar to that of responders except for increased use of inotropic agents (Table 1 ). This could be a reflection of compromised cardiovascular status among non-responders to iNO. There was no significant difference in the frequency of use of high frequency ventilation or surfactant administration between the two groups.
We found that a simple ratio of MHb/SNO was significantly lower among non-responders to iNO compared with responders (Table 3) . We observed a significant correlation between the changes in PaO 2 /FiO 2 and MHb/SNO ratios among all infants (Figure 1 ).
There are several limitations to this study. Being a retrospective chart review, the timing of MHb analysis in relation to duration of NO exposure was variable. The mean duration of exposure was slightly longer in the non-responder group and this could have contributed to a lower MHb/SNO ratio. Although MHb levels are definitely influenced by duration of exposure and dose of NO, 14 this is not a linear correlation. 11 Second, the MHb levels are dependent on the activity of MHb reductase enzyme and may vary among infants. Another significant limitation is that baseline MHb levels were not available in these infants. A change in MHb from baseline in individual babies after initiation of NO may be more indicative of NO diffusion than the mean values measured after several hours. Other factors such as level of fetal hemoglobin, pulmonary blood flow and cardiac output may influence the interaction between NO and hemoglobin. Increased need for inotropic medications among non-responders may indicate poor cardiac function and reduced quantity of blood (and hemoglobin) exposed to iNO. We plan to conduct a prospective trial among infants with (10, 20) 20 (12, 20) Hours of NO at initial methemoglobin level 2.9 ± 1.5 2.3 ± 2.6 Hemoglobin level (g per 100 ml) 15 ± 1. parenchymal disease and PPHN and obtain MHb levels before and exactly 2 h after initiation of 20 ppm of iNO.
We conclude that poor NO delivery, as evidenced by low MHb/SNO ratio, may be an important cause of a poor oxygenation response to NO in PPHN secondary to parenchymal lung disease. We speculate that MHb/SNO ratio may be used as a tool to assess delivery (and presumably availability) of inhaled NO to the pulmonary vasculature. Ventilation strategies to optimize alveolar recruitment, such as providing adequate PEEP, high frequency oscillatory ventilation and surfactant, may improve oxygenation response to inhaled NO in patients with low MHb/SNO ratio. Larger retrospective studies or prospective studies are necessary to establish the importance of this ratio in infants with PPHN requiring inhaled NO therapy.
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